Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOLASE, INCBIOL · Entity 11470 | Director | June 30, 2017 | July 03, 2017 |
| INTUITIVE SURGICAL INCISRG · Entity 2878 | Director | September 10, 2003 | September 12, 2003 |
| Intersect ENT, Inc.XENT · Entity 127294 | Director | January 19, 2021 | February 05, 2021 |
| Lux Health Tech Acquisition Corp.LUXA · Entity 145615 | Director | October 26, 2020 | October 26, 2020 |
| PROCEPT BioRobotics CorpPRCT · Entity 4831 | Director | June 09, 2026 | June 10, 2026 |
| SS Innovations International, Inc.SSII · Entity 5246 | Director · 10% owner | March 06, 2026 | March 10, 2026 |
| Venus Concept Inc.VERO · Entity 55304 | Director | November 07, 2019 | November 08, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOLASE, INC
Report date June 30, 2017 · Filed July 03, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 251,317 |
Reported balance
After 2017-06-30 transaction · row 1
1 source rowRow 1 · 2017-06-30 · Conversion · Acquired 192,100 · Balance 251,317 F1: On June 30, 2017, as a result of receipt of the Requisite Stockholder Approval (defined and described further in the Securities Purchase Agreement dated April 11, 2017 and filed as Exhibit 99.1 to the Current Report on Form 8-K filed by the Issuer on April 14, 2017), each share of Preferred Stock (as defined below) automatically converted into 100 shares of Common Stock, reflecting a conversion price equal to $1.24 per share. |
| Series D Participating Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.24 | Direct | 0 |
Reported balance
After 2017-06-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-30 · Conversion · Disposed 1,921 · Balance 0 F2: These shares of Series D Participating Convertible Preferred Stock ("Preferred Stock") were acquired by Frederic H. Moll in a private placement with the Issuer, which closed on April 18, 2017. F3: The Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 30, 2017, as a result of receipt of the Requisite Stockholder Approval (defined and described further in the Securities Purchase Agreement dated April 11, 2017 and filed as Exhibit 99.1 to the Current Report on Form 8-K filed by the Issuer on April 14, 2017), each share of Preferred Stock (as defined below) automatically converted into 100 shares of Common Stock, reflecting a conversion price equal to $1.24 per share.
F2: These shares of Series D Participating Convertible Preferred Stock ("Preferred Stock") were acquired by Frederic H. Moll in a private placement with the Issuer, which closed on April 18, 2017.
F3: The Preferred Stock had no expiration date.
INTUITIVE SURGICAL INC
Report date September 10, 2003 · Filed September 12, 2003
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 657,799 |
Ending reported balance
After 2003-09-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2003-09-10 · Sale · Disposed 5,000 · Balance 662,799 Row 2 · 2003-09-10 · Sale · Disposed 5,000 · Balance 657,799 |
Intersect ENT, Inc.
Report date January 19, 2021 · Filed February 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 260,961 |
Reported balance
After 2021-01-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-01-19 · Exercise / conversion · Acquired 12,500 · Balance 260,961 F1: Includes 5,011 restricted stock units. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2021-01-31 | Direct | 0 |
Reported balance
After 2021-01-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-19 · Exercise / conversion · Disposed 12,500 · Balance 0 F2: The vesting commencement date of the option is February 1, 2011. 7500 shares subject to the option vested on February 2, 2011 and 1/60th of the shares subject to the option vested monthly thereafter over 24 months. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 5,011 restricted stock units.
F2: The vesting commencement date of the option is February 1, 2011. 7500 shares subject to the option vested on February 2, 2011 and 1/60th of the shares subject to the option vested monthly thereafter over 24 months.
Lux Health Tech Acquisition Corp.
Report date October 26, 2020 · Filed October 26, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-10-26 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Class B common stock will automatically convert into shares of Class A common stock at the completion of the Issuer's initial business combination on a one-for-one basis, subject to adjustment. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B common stock will automatically convert into shares of Class A common stock at the completion of the Issuer's initial business combination on a one-for-one basis, subject to adjustment.
PROCEPT BioRobotics Corp
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 866,474 |
Reported balance
After 2026-06-09 transaction · row 1
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 3,315 · Balance 866,474 F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.78 · Expires 2036-06-08 | Direct | 5,853 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 5,853 · Balance 5,853 F2: The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
F2: The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
SS Innovations International, Inc.
Report date March 06, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 10,775,485 |
Reported balance
After 2026-03-06 transaction · row 1
1 source rowRow 1 · 2026-03-06 · Purchase · Acquired 501,253 · Balance 10,775,485 |
Venus Concept Inc.
Report date November 07, 2019 · Filed November 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 207,381 |
Reported balance
After 2019-11-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-11-07 · Grant · Acquired 145,394 · Balance 207,381 F1: Received in connection with the Merger, upon the conversion of the outstanidng principal and any accrued and unpaid interest of two 8% Convertible Promissory Notes issued by Venus Concept Ltd., dated as of August 14, 2019 and August 21, 2019, in the original principal amounts of $197,142.85 and $802,857.15, respectively. F2: Dr. Moll's previously reported holdings of common stock of the Issuer of 929,809 shares was adjusted to reflect the Issuer's 1-for-15 reverse stock split that occurred on November 7, 2019, which resulted in Dr. Moll's ownership of 867,822 less shares of common stock. |
| Common StockSEC Table I · non-derivative | Direct | 659,788 |
Reported balance
After 2019-11-07 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2019-11-07 · Conversion · Acquired 452,407 · Balance 659,788 F3: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 6,432,246 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019. F4: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664, which conversion occurred prior to the 1-for 15 reverse stock split that occurred on November 7, 2019. |
| Common StockSEC Table I · non-derivative | Direct | 950,553 |
Reported balance
After 2019-11-07 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2019-11-07 · Conversion · Acquired 290,765 · Balance 950,553 F5: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 4,288,164 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019. F4: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664, which conversion occurred prior to the 1-for 15 reverse stock split that occurred on November 7, 2019. |
| Unsecured Subordinated Convertible Promissory NoteSEC Table II · derivative / convertible security · Expires 2020-08-28 | Direct | 0 |
Reported balance
After 2019-11-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-07 · Conversion · Disposed Not disclosed · Balance 0 F4: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664, which conversion occurred prior to the 1-for 15 reverse stock split that occurred on November 7, 2019. F6: Through the date of conversion, the principal and interest under this Unsecured Subordinated Convertible Promissory Note, totaled $3,165,041.10 which total was converted into shares of common stock of the Issuer. F7: This Unsecured Subordinated Convertible Promissory Note converted upon the consumation of the Merger, pursuant to its terms. F3: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 6,432,246 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019. |
| Unsecured Subordinated Convertible Promissory NoteSEC Table II · derivative / convertible security · Expires 2020-08-28 | Direct | 0 |
Reported balance
After 2019-11-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-07 · Conversion · Disposed Not disclosed · Balance 0 F4: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664, which conversion occurred prior to the 1-for 15 reverse stock split that occurred on November 7, 2019. F8: Through the date of conversion, the principal and interest under this Unsecured Subordinated Convertible Promissory Note, totaled $2,034,191.85 which total was converted into shares of common stock of the Issuer. F7: This Unsecured Subordinated Convertible Promissory Note converted upon the consumation of the Merger, pursuant to its terms. F5: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 4,288,164 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Received in connection with the Merger, upon the conversion of the outstanidng principal and any accrued and unpaid interest of two 8% Convertible Promissory Notes issued by Venus Concept Ltd., dated as of August 14, 2019 and August 21, 2019, in the original principal amounts of $197,142.85 and $802,857.15, respectively.
F2: Dr. Moll's previously reported holdings of common stock of the Issuer of 929,809 shares was adjusted to reflect the Issuer's 1-for-15 reverse stock split that occurred on November 7, 2019, which resulted in Dr. Moll's ownership of 867,822 less shares of common stock.
F3: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 6,432,246 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019.
F4: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664, which conversion occurred prior to the 1-for 15 reverse stock split that occurred on November 7, 2019.
F5: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 4,288,164 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019.
F6: Through the date of conversion, the principal and interest under this Unsecured Subordinated Convertible Promissory Note, totaled $3,165,041.10 which total was converted into shares of common stock of the Issuer.
F7: This Unsecured Subordinated Convertible Promissory Note converted upon the consumation of the Merger, pursuant to its terms.
F8: Through the date of conversion, the principal and interest under this Unsecured Subordinated Convertible Promissory Note, totaled $2,034,191.85 which total was converted into shares of common stock of the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Shockwave Medical, Inc.
Report date May 31, 2024 · Filed May 31, 2024
Section 16 reporting ended · disclosed 2024-05-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 1
1 source rowRow 1 · 2024-05-31 · Disposition to issuer · Disposed 287,521 · Balance 0 F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2029-03-06 | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-31 · Disposition to issuer · Disposed 17,381 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.20 · Expires 2025-06-16 | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-31 · Disposition to issuer · Disposed 16,393 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"),
F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration.
F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 10, 2026 20:40 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantStock Option (Right to Buy) · Derivative | 5,853 | $0.00 Strike: $28.78 | $0.00 |
DisclosureSEC source: 0001628280-26-042260 · wk-form4_1781124012.xml · derivative · entry 2 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,853 Underlying: Common Stock · 5,853 shares Expires 2036-06-08 F2 · derivative.exercise_date: The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 20:40 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock | 3,315 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-042260 · wk-form4_1781124012.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 866,474 F1 · kind: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 22:05 UTC | SS Innovations International, Inc. SSII · Entity 5246 | PurchaseCommon Stock, $0.0001 par value | 501,253 | $3.99 | $1,999,999.47 |
DisclosureSEC source: 0001213900-26-025795 · ownership.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,775,485 Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 20:18 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | PurchaseCommon Stock | 20,000 | $39.26 | $785,138.00 |
DisclosureSEC source: 0001628280-25-040397 · wk-form4_1755202701.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 863,159 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $38.71 to $39.645, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:27 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantStock Option (Right to Buy) · Derivative | 2,771 | $0.00 Strike: $64.23 | $0.00 |
DisclosureSEC source: 0001628280-25-030996 · wk-form4_1749760050.xml · derivative · entry 2 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,771 Underlying: Common Stock · 2,771 shares Expires 2035-06-09 F2 · derivative.exercise_date: The Stock option was granted on June 10, 2025 and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:27 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock | 1,538 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-030996 · wk-form4_1749760050.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 843,159 F1 · kind: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 22:00 UTC | SS Innovations International, Inc. SSII · Entity 5246 | PurchaseCommon Stock, $0.0001 par value | 3,645,224 | $1.37 | $5,001,247.33 |
DisclosureSEC source: 0001213900-25-016651 · ownership.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Frederic Hutchins Moll Revocable Trust Disclosed balance after: 10,060,813 F1 · ownership.nature: The reporting person has a 100% interest in the Frederic Hutchins Moll Revocable Trust which holds the shares of SSII covered by this report. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:39 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,263 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001628280-25-005209 · wk-form4_1739399980.xml · derivative · entry 4 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,263 shares Expires 2025-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Stock option is fully vested and exercisable. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:39 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,749 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001628280-25-005209 · wk-form4_1739399980.xml · derivative · entry 3 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,749 shares Expires 2025-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Stock option is fully vested and exercisable. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:39 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionCommon Stock | 5,263 | $0.86 | $4,526.18 |
DisclosureSEC source: 0001628280-25-005209 · wk-form4_1739399980.xml · nonDerivative · entry 2 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 841,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:39 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionCommon Stock | 26,749 | $1.33 | $35,576.17 |
DisclosureSEC source: 0001628280-25-005209 · wk-form4_1739399980.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 836,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2025 Filed Jan 10, 2025 21:20 UTC | SS Innovations International, Inc. SSII · Entity 5246 | PurchaseCommon Stock, $0.0001 par value | 1,457,726 | $1.37 | $2,000,000.07 |
DisclosureSEC source: 0001213900-25-002667 · ownership.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Sonder Futures II, L.P. Disclosed balance after: 1,457,726 F1 · ownership.nature: The Reporting Person is a member of the general partner of Sonder Futures II, L.P. which holds the shares covered by this report. Together with the other members of the general partner of Sonder Futures II, L.P., the reporting person has shared voting and dispositive power over the shares covered by this report. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:00 UTC | SS Innovations International, Inc. SSII · Entity 5246 | PurchaseCommon Stock, $0.0001 par value | 2,186,589 | $1.37 | $3,000,000.11 |
DisclosureSEC source: 0001213900-25-000831 · ownership.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Frederic Hutchins Moll Revocable Trust Disclosed balance after: 6,415,589 F1 · ownership.nature: The reporting person has a 100% interest in the Frederic Hutchins Moll Revocable Trust which holds the shares of SSII covered by this report. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 22:00 UTC | SS Innovations International, Inc. SSII · Entity 5246 | PurchaseCommon Stock, $0.0001 par value | 3,644,315 | $1.37 | $5,000,000.18 |
DisclosureSEC source: 0001213900-24-103553 · ownership.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Frederic Hutchins Moll Revocable Trust Disclosed balance after: 4,229,000 F1 · ownership.nature: The reporting person has a 100% interest in the Frederic Hutchins Moll Revocable Trust which holds the shares of SSII covered by this report. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:25 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantStock Option (Right to Buy) · Derivative | 2,526 | $0.00 Strike: $67.29 | $0.00 |
DisclosureSEC source: 0001628280-24-027040 · wk-form4_1717705537.xml · derivative · entry 2 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,526 Underlying: Common Stock · 2,526 shares Expires 2034-06-03 F2 · derivative.exercise_date: The Stock Option was granted on June 4, 2024 and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:25 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock | 1,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027040 · wk-form4_1717705537.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 809,609 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| May 31, 2024 Filed May 31, 2024 20:41 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Disposition to issuerStock Option · Derivative | 16,393 | Not disclosed Strike: $2.20 | Not disclosed |
DisclosureSEC source: 0001642545-24-000121 · wk-form4_1717188091.xml · derivative · entry 3 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,393 shares Expires 2025-06-16 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. Read SEC document |
| May 31, 2024 Filed May 31, 2024 20:41 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Disposition to issuerStock Option · Derivative | 17,381 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001642545-24-000121 · wk-form4_1717188091.xml · derivative · entry 2 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,381 shares Expires 2029-03-06 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. Read SEC document |
| May 31, 2024 Filed May 31, 2024 20:41 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Disposition to issuerCommon Stock | 287,521 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001642545-24-000121 · wk-form4_1717188091.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2 · price: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 01:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,200 | $261.96 | $314,352.00 |
DisclosureSEC source: 0001642545-24-000055 · wk-form4_1708650890.xml · nonDerivative · entry 8 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,521 F8 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $261.54 to $262.40. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 01:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 4,890 | $260.80 | $1,275,312.00 |
DisclosureSEC source: 0001642545-24-000055 · wk-form4_1708650890.xml · nonDerivative · entry 7 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,721 F7 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $260.45 to $261.42. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 01:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 5,528 | $259.91 | $1,436,782.48 |
DisclosureSEC source: 0001642545-24-000055 · wk-form4_1708650890.xml · nonDerivative · entry 6 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,611 F6 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $259.44 to $260.42. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 01:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 2,660 | $258.95 | $688,807.00 |
DisclosureSEC source: 0001642545-24-000055 · wk-form4_1708650890.xml · nonDerivative · entry 5 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 299,139 F5 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $258.43 to $259.42. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 01:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 8,649 | $258.09 | $2,232,220.41 |
DisclosureSEC source: 0001642545-24-000055 · wk-form4_1708650890.xml · nonDerivative · entry 4 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 301,799 F4 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $257.43 to $258.39. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 01:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 14,165 | $256.82 | $3,637,855.30 |
DisclosureSEC source: 0001642545-24-000055 · wk-form4_1708650890.xml · nonDerivative · entry 3 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,448 F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $256.43 to $257.29. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 01:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 16,464 | $255.95 | $4,213,960.80 |
DisclosureSEC source: 0001642545-24-000055 · wk-form4_1708650890.xml · nonDerivative · entry 2 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 324,613 F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $255.43 to $256.42. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 01:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 6,444 | $255.14 | $1,644,122.16 |
DisclosureSEC source: 0001642545-24-000055 · wk-form4_1708650890.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,077 F1 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $254.43 to $255.42. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 08, 2024 Filed Feb 10, 2024 01:07 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 81,967 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001642545-24-000042 · wk-form4_1707527245.xml · derivative · entry 2 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 81,967 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| February 08, 2024 Filed Feb 10, 2024 01:07 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 81,967 | $0.61 | $49,999.87 |
DisclosureSEC source: 0001642545-24-000042 · wk-form4_1707527245.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The total reported in Column 5 of Table I includes 33,960 shares of the issuer's common stock previously held by MBL-2 Holdings LLC (the "LLC"), which were previously distributed, for no consideration, to the reporting person's direct ownership in a transaction exempt from reporting pursuant to Rule 16a-13. The reporting person is the sole managing member of the LLC. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 22:33 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 27,242 | $39.25 | $1,069,158.60 |
DisclosureSEC source: 0001628280-23-041163 · wk-form4_1702074773.xml · nonDerivative · entry 2 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 808,233 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.180 to $40.1799, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 22:33 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 51,758 | $38.49 | $1,992,196.47 |
DisclosureSEC source: 0001628280-23-041163 · wk-form4_1702074773.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 835,475 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.1800 to $39.1799, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:52 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantStock Option (Right to Buy) · Derivative | 4,865 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001628280-23-022502 · wk-form4_1686948758.xml · derivative · entry 2 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,865 Underlying: Common Stock · 4,865 shares Expires 2033-06-14 F2 · derivative.exercise_date: The Stock Option was granted on June 15, 2023 and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:52 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock | 2,711 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-022502 · wk-form4_1686948758.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 887,233 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:50 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GrantCommon Stock | 736 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037556 · doc4.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,594 Read SEC document |
| September 02, 2022 Filed Feb 15, 2023 02:05 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GiftCommon Stock | 33,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009585 · doc5.xml · nonDerivative · entry 4 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,858 F4 · shares: This transaction represents a contribution, for no consideration, of shares of the issuer's common stock to MBL-2 Holdings LLC, of which the reporting person is the sole managing member. Read SEC document |
| September 01, 2022 Filed Feb 15, 2023 02:05 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GiftCommon Stock | 9,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009585 · doc5.xml · nonDerivative · entry 3 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,818 F3 · shares: This transaction represents a gift of stock by the reporting person to the LVM 2022 Trust (the "Trust"), which is an irrevocable trust established for the benefit of one of his adult children. The reporting person is neither a trustee nor a beneficiary and he disclaims beneficial ownership of all securities owned by the Trust. Read SEC document |
| September 01, 2022 Filed Feb 15, 2023 02:05 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GiftCommon Stock | 9,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009585 · doc5.xml · nonDerivative · entry 2 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,118 F2 · shares: This transaction represents a gift of stock by the reporting person to one of his adult children. Read SEC document |
| September 01, 2022 Filed Feb 15, 2023 02:05 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GiftCommon Stock | 9,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009585 · doc5.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,418 F1 · shares: This transaction represents a gift of stock by the reporting person to one of his adult children. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 23:56 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GrantCommon Stock | 994 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039542 · doc4.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,718 Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:15 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock · Derivative | 4,205 | $0.00 Strike: $38.85 | $0.00 |
DisclosureSEC source: 0001628280-22-016689 · wf-form4_165480570069698.xml · derivative · entry 2 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,205 Underlying: Common Stock · 4,205 shares Expires 2032-06-06 F2 · price: The Stock option was granted on June 7, 2022 and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. F2 · derivative.exercise_date: The Stock option was granted on June 7, 2022 and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:15 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock | 2,001 | $37.48 | $74,997.48 |
DisclosureSEC source: 0001628280-22-016689 · wf-form4_165480570069698.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 884,522 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 22:29 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 12,295 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001209191-21-067315 · doc4.xml · derivative · entry 2 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,295 shares Expires 2021-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vested on 6/21/2012 and the balance of the shares vested in equal monthly installments thereafter for 36 months. Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 22:29 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 12,295 | $0.49 | $5,999.96 |
DisclosureSEC source: 0001209191-21-067315 · doc4.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 22:34 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | ConversionSeries G Convertible Preferred Stock · Derivative | 60,172 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001628280-21-018954 · wf-form4_163226367108643.xml · derivative · entry 8 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,172 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. F1 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 22:34 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | ConversionSeries F Convertible Preferred Stock · Derivative | 16,974 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001628280-21-018954 · wf-form4_163226367108643.xml · derivative · entry 7 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,974 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. F1 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 22:34 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | ConversionSeries E Convertible Preferred Stock · Derivative | 9,104 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001628280-21-018954 · wf-form4_163226367108643.xml · derivative · entry 6 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,104 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. F1 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 22:34 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | ConversionSeries D Convertible Preferred Stock · Derivative | 108,214 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001628280-21-018954 · wf-form4_163226367108643.xml · derivative · entry 5 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 108,214 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. F1 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 22:34 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | ConversionSeries C Convertible Preferred Stock · Derivative | 89,840 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001628280-21-018954 · wf-form4_163226367108643.xml · derivative · entry 4 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 89,840 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. F1 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 22:34 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | ConversionSeries B Convertible Preferred Stock · Derivative | 45,586 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001628280-21-018954 · wf-form4_163226367108643.xml · derivative · entry 3 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,586 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. F1 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 22:34 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | PurchaseCommon Stock | 400,000 | $25.00 | $10,000,000.00 |
DisclosureSEC source: 0001628280-21-018954 · wf-form4_163226367108643.xml · nonDerivative · entry 2 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 882,521 F2 · shares: Represents a purchase in the Issuer's public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.